Observation on clinical effect of dapagliflozin combined with tripterygium wilfordii in the treatment of early type 2 diabetic nephropathy
Objective To study the clinical efficacy of dapagliflozin combined with tripterygium wilfordii in the treatment of early type 2 diabetic nephropathy.Methods 74 patients with early type 2 diabetic nephropathy were divided into an observation group and a control group according to random number table method,with 37 cases in each group.The control group was treated with tripterygium wilfordii,and the observation group was treated with dapagliflozin on the basis of the control group.Both groups were compared in terms of total effective rate of clinical treatment,serum renal fibrosis indicators[laminin(LN),hyaluronic acid(HA),type Ⅲ procollagen(PCⅢ),type Ⅳ collagen(Ⅳ-C)],immune function(CD4+,CD8+),renal function indicators[urine albumin excretion rate(UAER),cystatin C(CysC),and serum creatinine(Scr)].Results The total effective rate of clinical treatment of the observation group was 89.19%,which was higher than 54.05%of the control group(P<0.05).After treatment,LN,HA,PCⅢ and Ⅳ-C in both groups were better than those before treatment;LN,HA,PCⅢ and Ⅳ-C in the observation group were(91.68±10.16),(176.15±20.27),(127.11±14.92)and(95.32±10.27)ng/ml,which were better than(103.56±12.56),(206.19±23.62),(145.75±15.82)and(110.64±13.25)ng/ml in the control group(P<0.05).After treatment,CD4+ and CD8+ in both groups were better than those before treatment;CD4+ and CD8+ in the observation group were(48.97±5.24)%and(19.82±2.52)%,which were better than(42.79±4.99)%and(24.86±3.61)%in the control group(P<0.05).After treatment,UAER,CysC and Scr in both groups were better than those before treatment;UAER,CysC and Scr in the observation group were(106.25±7.91)μg/min,(114.53±15.49)μmol/L and(1.31±0.06)mg/L,which were better than(172.51±5.79)μg/min,(122.49±12.48)μmol/L and(1.59±0.11)mg/L in the control group(P<0.05).Conclusion The treatment of patients with early type 2 diabetic nephropathy by dapagliflozin combined with tripterygium wilfordii can effectively improve clinical efficacy and treatment indicators,and it is worth promoting.
DapagliflozinTripterygium wilfordiiEarly type 2 diabetic nephropathyClinical efficacy
万方数据
维普
